London · Delayed Price · Currency is GBP · Price in GBX Faron Pharmaceuticals Oy Earnings Call Transcripts
Fiscal Year 2026
-
Bexmarilimab targets CLEC-1 on macrophages, showing strong efficacy and safety in high-risk MDS, with a 45% CR rate and extended survival. A €40 million fully committed rights offering will fund a pivotal phase IIb trial and multiple solid tumor studies, positioning the asset for major commercial and partnership opportunities.
-
High and durable response rates in high-risk MDS have led to a revised, de-risked trial design using CR as the approval endpoint, supported by FDA guidance. Partnering interest is strong, with a new value inflection point expected from Phase II data in November.
Fiscal Year 2025
-
Outstanding clinical results in high-risk MDS, improved financial position, and a robust pipeline set the stage for a pivotal phase 2b trial and expansion into new indications. Planned EUR 40 million rights offering aims to fund key milestones.
-
Bexmarilimab plus azacitidine demonstrated strong efficacy and safety in high-risk and HMA-failed MDS, with particularly high response rates in low blast count patients. A pivotal phase 2/3 trial is planned, and development is expanding into AML, solid tumors, and autoimmune indications.
-
H1 2025 saw major clinical and financial progress, highlighted by positive phase II results for BEX in high-risk MDS, a strong cash position, and FDA alignment on a pivotal trial with accelerated approval possible in 2028. The oncology pipeline expanded, and new financing secured.
-
Phase 2 results for bexmarilimab plus azacitidine in high-risk MDS show strong response rates and favorable safety, including in TP53-mutant patients. The FDA supports a single pivotal Phase 3 trial, with plans to initiate in H1 next year and potential for accelerated approval if interim results are positive.
Fiscal Year 2024
-
Cash position improved with €35.5M raised in 2024 and €12M in early 2025, while losses narrowed. Bexmarilimab advanced with strong clinical results and multiple regulatory fast-tracks; phase 2 top-line data is expected in April 2025.
-
Interim results from the BEXMAB trial in relapsed/refractory MDS show an 80% overall response rate, excellent safety, and a median survival of 13.4 months, outperforming current therapies. Regulatory designations and trial expansion support rapid development and future phase III plans.
-
Bexmarilimab is advancing as a potential cornerstone therapy for cancers with CLEVER-1 macrophage-driven resistance, with strong phase II MDS data, robust market enthusiasm, and a strategic focus on cost-effective proof-of-concept trials. Key milestones include a pivotal phase II readout and solid tumor trial launches.
-
H1 saw record fundraising, leadership changes, and strong clinical progress, including FDA Fast Track for bexmarilimab. Cash runway extends into Q1 2025, but additional funding or partnership is needed for phase III.